Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.36 |
| ▸ | ACE | P12821 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | FNTA | P49354 | 1/20 | 0.35 |
| ▸ | FNTB | P49356 | 1/20 | 0.35 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7375020 | 0.90 | CYP11B1 (0.39) | CYP11B1CYP11B2ACE2ACE | |
| SCHEMBL7382224 | 0.89 | CYP11B1 (0.41) | CYP11B1CYP11B2ACE2ACEFNTA | |
| SCHEMBL7374943 | 0.89 | CYP11B1 (0.39) | CYP11B1CYP11B2ACE2ACESMN1; SMN2 | |
| SCHEMBL7398066 | 0.88 | CYP11B1 (0.37) | CYP11B1CYP11B2ACE2ACEMEN1 | |
| SCHEMBL1655292 | 0.87 | CYP11B1 (0.36) | CYP11B1CYP11B2ACE2ACEFNTA | |
| SCHEMBL7384141 | 0.86 | ALDH1A1 (0.39) | CYP11B1CYP11B2 | |
| SCHEMBL7383285 | 0.86 | ACE2 (0.38) | CYP11B1CYP11B2ACE2ACE | |
| SCHEMBL3686724 | 0.86 | CYP11B1 (0.35) | CYP11B1CYP11B2ACE2ACE | |
| SCHEMBL3715181 | 0.84 | ACE2 (0.43) | CYP11B1CYP11B2ACE2ACEFNTA | |
| SCHEMBL3712509 | 0.83 | ACE2 (0.41) | CYP11B1CYP11B2ACE2ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010093804-A1 | ACE2 INHIBITORS FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS | ORE PHARMACEUTICALS, INC. (US) | 2010-08-19 | — | — | WO | claimed |
| WO-2009049022-A1 | METHOD FOR TREATMENT OF PANCREATITIS | ORE PHARMACEUTICALS INC. (US) | 2009-04-16 | — | — | WO | claimed |
| WO-2000066104-A9 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2002-08-29 | — | — | WO | claimed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | claimed |
| EP-3717077-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2020-10-07 | — | — | EP | disclosed |
| WO-2010093804-A1 | ACE2 INHIBITORS FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS | ORE PHARMACEUTICALS, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2000066104-A9 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| EP-1183019-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000066104-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-11-09 | — | — | WO | disclosed |